Social impact
Drug and vaccine policy

Luxembourg for the first time in the WAIT Indicator

Improving the availability of medicines authorised in the European Union (EU) is a crucial priority for the European medicines regulatory network and for the pharmaceutical industry. This year’s iteration of the Patients W.A.I.T. (Waiting to Access Innovative Therapies) Indicator has been running in evolving formats since 2004. It is the most extensive European study into innovative medicines availability and the time to patient access.

The charts in the following report cover a broader set of countries than in previous years. In the publication, data on 39 countries (27 EU and 12 non-EU) are included giving a complete European picture of availability.

In 2022, Luxembourg is part of this study for the first time. The figures of Luxembourg included the medicines with a public reimbursement price and every medicine distributed through the hospital pharmacy  (product D and H in commercialised medicines) is 100 % supported by the hospital's budget (free for the patient).

Become a member

Keep up to date with iml.lu

The flash letter informs you regularlay about the news of our sector in Luxembourg, the news of the research in Luxembourg, within our members and finally about the news of the association.  Don't waste a minute and subscribe.